{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T01:11:27Z","timestamp":1782868287853,"version":"3.54.5"},"reference-count":10,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Clinical Electrophysiology"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.jacep.2023.01.034","type":"journal-article","created":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T15:02:45Z","timestamp":1679497365000},"page":"1181-1183","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"P2","title":["Are Class IC Antiarrhythmic Agents Safe\u00a0in Atrial Fibrillation Patients With\u00a0Nonobstructive Coronary Artery\u00a0Disease?"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8196-4554","authenticated-orcid":false,"given":"Gerald V.","family":"Naccarelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacep.2023.01.034_bib1","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1056\/NEJM199103213241201","article-title":"Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial","volume":"324","author":"Echt","year":"1991","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacep.2023.01.034_bib2","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0002-9149(96)00673-X","article-title":"Impact of the Food and Drug Administration approval of flecainide and encainide on coronary artery disease mortality: putting \u201cdeadly medicine\u201d to the test","volume":"79","author":"Anderson","year":"1997","journal-title":"Am J Cardiol"},{"issue":"1","key":"10.1016\/j.jacep.2023.01.034_bib3","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jacc.2019.01.011","article-title":"2019 AHA\/ACC\/HRS focused update of the 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation","volume":"74","author":"January","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacep.2023.01.034_bib4","first-page":"1172","article-title":"The feasibility and safety of flecainide use among patients with varying degrees of coronary disease","volume":"9","author":"Kiani","year":"2023","journal-title":"J\u00a0Am Coll Cardiol EP"},{"key":"10.1016\/j.jacep.2023.01.034_bib5","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/0002-9149(94)90308-5","article-title":"Beta-blocker therapy in the Cardiac Arrhythmia Suppression Trial. CAST Investigators","volume":"74","author":"Kennedy","year":"1994","journal-title":"Am J Cardiol"},{"issue":"3","key":"10.1016\/j.jacep.2023.01.034_bib6","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/jce.14335","article-title":"Class 1C antiarrhythmic drugs in atrial fibrillation and coronary artery disease","volume":"31","author":"Pantlin","year":"2020","journal-title":"J\u00a0Cardiovasc Electrophysiol"},{"key":"10.1016\/j.jacep.2023.01.034_bib7","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ahj.2021.08.013","article-title":"Long-term outcomes in patients treated with flecainide for atrial fibrillation in patients with stable coronary artery disease","volume":"243","author":"Burnham","year":"2022","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacep.2023.01.034_bib8","first-page":"1","article-title":"Use of flecainide in stable coronary artery disease: an analysis of its safety in both nonobstructive and obstructive coronary artery disease","author":"Ashraf","year":"2021","journal-title":"Am J Cardiovasc Drugs"},{"issue":"2","key":"10.1016\/j.jacep.2023.01.034_bib9","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s10840-022-01186-0","article-title":"Propafenone use in coronary artery disease patients undergoing atrial fibrillation ablation","volume":"65","author":"Cay","year":"2022","journal-title":"J\u00a0Interv Card Electrophysiol"},{"key":"10.1016\/j.jacep.2023.01.034_bib10","doi-asserted-by":"crossref","first-page":"I47","DOI":"10.1093\/eurheartjsupp\/suac073","article-title":"The many NOs to the use of Class IC antiarrhythmics: weren\u2019t the guidelines too strict?","volume":"24","author":"Turturiello","year":"2022","journal-title":"Eur Heart J"}],"container-title":["JACC: Clinical Electrophysiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405500X23000968?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405500X23000968?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T07:32:48Z","timestamp":1762500768000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405500X23000968"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":10,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S2405500X23000968"],"URL":"https:\/\/doi.org\/10.1016\/j.jacep.2023.01.034","relation":{},"ISSN":["2405-500X"],"issn-type":[{"value":"2405-500X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Are Class IC Antiarrhythmic Agents Safe\u00a0in Atrial Fibrillation Patients With\u00a0Nonobstructive Coronary Artery\u00a0Disease?","name":"articletitle","label":"Article Title"},{"value":"JACC: Clinical Electrophysiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacep.2023.01.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jacep.2022.12.021","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}